Restriction of intestinal stem cell expansion and the regenerative response by YAP

Evan Barry, Teppei Morikawa, Brian L. Butler, +9

Nature

Mst1 and Mst2 protein kinases restrain intestinal stem cell proliferation and colonic tumorigenesis by inhibition of Yes-associated protein (Yap) overabundance

Dawang Zhou, Yongyou Zhang, Hongtan Wu, +8

Proceedings of the National Academy of Sciences

Colonic TumorigenesisTranscriptional RegulationTissue DevelopmentSignaling PathwayCell Regulation +19

ES Cell Cycle Progression and Differentiation Require the Action of the Histone Methyltransferase Dot1L

Evan Barry, Winfried Krueger, Caroline M. Jakuba, +4

Stem Cells

Histone ModificationsEpigenetic ChangeGeneticsCell CycleLysine 79 +18

The MET Inhibitor AZD6094 (Savolitinib, HMPL-504) Induces Regression in Papillary Renal Cell Carcinoma Patient–Derived Xenograft Models

Alwin G. Schuller, Evan Barry, Rhys D.O. Jones, +16

Clinical Cancer Research

<i> <scp>HUWE</scp> 1 </i> is a critical colonic tumour suppressor gene that prevents <scp>MYC</scp> signalling, <scp>DNA</scp> damage accumulation and tumour initiation

Kevin Myant, Patrizia Cammareri, Michael C. Hodder, +15

EMBO Molecular Medicine

Discovery of <i>N</i>-(4-{[5-Fluoro-7-(2-methoxyethoxy)quinazolin-4-yl]amino}phenyl)-2-[4-(propan-2-yl)-1<i>H</i>-1,2,3-triazol-1-yl]acetamide (AZD3229), a Potent Pan-KIT Mutant Inhibitor for the Treatment of Gastrointestinal Stromal Tumors

Jason G. Kettle, Rana Anjum, Evan Barry, +23

Journal of Medicinal Chemistry

Tyrosine Kinase PdgfrαPharmacotherapyPharmaceutical ChemistryTumor BiologySystems Pharmacology +19

Acquired savolitinib resistance in non-small cell lung cancer arises via multiple mechanisms that converge on MET-independent mTOR and MYC activation

Ryan E. Henry, Evan Barry, Lillian Castriotta, +13

Oncotarget

Multiple MechanismsMet-independent MtorCancer DeathCancer BiologyTumor Biology +14

Effective combination therapies in preclinical endocrine resistant breast cancer models harboring ER mutations

Brendon Ladd, Anne Marie Mazzola, Teeru Bihani, +17

Oncotarget

Discovery and pharmacological characterization of AZD3229, a potent KIT/PDGFRα inhibitor for treatment of gastrointestinal stromal tumors

Erica Banks, Michael Grondine, Deepa Bhavsar, +21

Science Translational Medicine

The Pharmacokinetic–Pharmacodynamic (PKPD) Relationships of AZD3229, a Novel and Selective Inhibitor of KIT, in a Range of Mouse Xenograft Models of GIST

Venkatesh Pilla Reddy, Rana Anjum, Michael Grondine, +9

Clinical Cancer Research